Business
CorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing
About this update from Cormedix Inc.
[{"type":"text","content":"BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has entered into a new three-year Employment Agreement with Liz Masson-Hurlburt, currently Executive Vice President and Head of Clinical Operations. The new agreement terminates in March 2024, and may be extended annually thereafter upon mutual agreement. “I am delighted that Liz has agreed to continue in her current role at this critical time as we are continuing to work toward a potential FDA approval of DefenCath and in parallel laying the groundwork for programs to advance DefenCath into other patient segments beyond hemodialysis,” said Khoso Baluch, Chief Executive Officer of CorMedix. “She has been instrumental in bringing the LOCK-IT 100 clinical study to a successful completion and assisting in the responses to the FDA during the review of the New Drug Application. Her expertise in clinical operations will be important as we develop potential indications for DefenCath in oncology and total parenteral nutrition.” Ms. Masson-Hurlburt joined CorMedix in March 2018 and was instrumental in bringing the LOCK-IT-100 clinical study to a successful completion. Prior to CorMedix, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as Vice President, Clinical Operations. Responsible for strategic and operational development activities, Liz has a passion for growing and developing highly engaged teams and assuring the highest standards for program execution. Liz received her B.A. in Leadership and Organizational Management from Bay Path College. About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Pr...